Related Experiment Video
Updated: May 6, 2026

Ex vivo Culture of Human Placental Explants for the Study of Viral Transmission Across the Maternal-Fetal Interface
Published on: December 30, 2025
Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy
Carla E Ransom1, Yanling Huo, Kunjal Patel
1*Department of Obstetrics and Gynecology, Vanderbilt University, Nashville, TN; †Center for Biostatistics in AIDS Research and ‡Department of Epidemiology, Harvard School of Public Health, Boston, MA; §Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL; ‖Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, MD; and ¶Department of Obstetrics and Gynecology, Duke University Medical School, Durham, NC.
Objective:
To determine whether maternal use of tenofovir disoproxil fumarate for treatment of HIV in pregnancy predicts fetal and infant growth.
Methods:
The study population included HIV-uninfected live-born singleton infants of mothers enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group protocol P1025 (born 2002-2011) in the United States and exposed in utero to a combined (triple or more) antiretroviral regimen. Infant weight at birth and 6 months was compared between infants exposed and unexposed to tenofovir in utero using 2-sample t test, χ test, and multivariable linear and logistic regression models, including demographic and maternal characteristics.
Results:
Among 2025 infants with measured birth weight, there was no difference between those exposed (N = 630, 31%) versus unexposed to tenofovir in mean birth weight (2.75 vs. 2.77 kg, P = 0.64) or mean gestational age- and sex-adjusted birth weight z-score (WASZ) (0.14 vs. 0.14, P = 0.90). Among 1496 infants followed for 6 months, there was no difference in mean weight at 6 months between tenofovir-exposed (N = 457, 31%) and tenofovir-unexposed infants (7.64 vs. 7.59 kg, P = 0.52) or in mean WASZ (0.29 vs. 0.26, P = 0.61). Tenofovir exposure during the second/third trimester, relative to no exposure, significantly predicted underweight (WASZ < 5%) at age 6 months [odds ratio (95% confidence interval): 2.06 (1.01 to 3.95), P = 0.04]. Duration of tenofovir exposure did not predict neonatal or infant growth.
Conclusions:
By most measures, in utero exposure to tenofovir did not significantly predict infant birth weight or growth through 6 months of age.
More Related Videos
03:19Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes
Published on: June 28, 2024
09:04Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
Related Concept Videos
Teratogenicity
Development of the Oral Microbiota
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Excretion
Development of Human Microbiota
Intrauterine Drug Delivery Systems